No black box warning on record for Depo-Estradiol

As of the latest FDA labeling reviewed, Depo-Estradiol (ESTRADIOL CYPIONATE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Depo-Estradiol medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS See BOXED WARNINGS 1. Cardiovascular disorders Estrogen and estrogen/progestin therapy have been associated with an increased risk of cardiovascular events such as myocardial infarction and stroke, as well as venous thrombosis and pulmonary embolism (venous thromboembolism or VTE). Should any of these occur or be suspected, estrogens should be discontinued immediately. Risk factors for ar

No black box warning on record for Depo-Estradiol

Other warnings & precautions

WARNINGS See BOXED WARNINGS 1. Cardiovascular disorders Estrogen and estrogen/progestin therapy have been associated with an increased risk of cardiovascular events such as myocardial infarction and stroke, as well as venous thrombosis and pulmonary embolism (venous thromboembolism or VTE). Should any of these occur or be suspected, estrogens should be discontinued immediately. Risk factors for ar

Depo-Estradiol Black Box Warning

No black box warning on record for Depo-Estradiol

Other warnings & precautions

Depo-Estradiol Black Box Warning

No black box warning on record for Depo-Estradiol

Other warnings & precautions